Mycophenolate mofetil - Roche

Drug Profile

Mycophenolate mofetil - Roche

Alternative Names: CellCept; Cellcept Capsules; ME MPA; Munoloc; R99; RS-61443

Latest Information Update: 17 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche Palo Alto LLC
  • Developer Aspreva Pharmaceuticals Corporation; Chugai Pharmaceutical; Roche; Roche Palo Alto
  • Class Acyclic acids; Fatty acids; Small molecules
  • Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pemphigus vulgaris; Myasthenia gravis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart transplant rejection; Liver transplant rejection; Lung transplant rejection; Lupus nephritis; Pancreas transplant rejection; Renal transplant rejection; Transplant rejection
  • Discontinued Multiple sclerosis; Myasthenia gravis; Pemphigus vulgaris; Psoriasis

Most Recent Events

  • 14 May 2016 Launched for Lupus nephritis in Japan (PO, Capsule)
  • 14 May 2016 Launched for Lupus nephritis in Japan (PO, Powder)
  • 13 May 2016 Registered for Lupus nephritis in Japan (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top